Horimoto Y - Search Results

1

Efficacy of radiation therapy in Japanese patients with positive margins after breast-conserving surgery.

Uomori T, Horimoto Y, Ueki Y, Ishizuka Y, Onagi H, Hayashi T, Watanabe J, Shikama N. Uomori T, et al. Among authors: horimoto y. Jpn J Clin Oncol. 2024 May 7;54(5):556-561. doi: 10.1093/jjco/hyad196. Jpn J Clin Oncol. 2024. PMID: 38251759

2

Pathology of healing: what else might we look at?

Horimoto Y, Hayashi T, Arakawa A. Horimoto Y, et al. Cancer Med. 2016 Dec;5(12):3586-3587. doi: 10.1002/cam4.952. Epub 2016 Oct 26. Cancer Med. 2016. PMID: 27781408 Free PMC article.

3

Relationship between alcohol metabolism and chemotherapy-induced emetic events in breast cancer patients.

Uomori T, Horimoto Y, Mogushi K, Matsuoka J, Saito M. Uomori T, et al. Among authors: horimoto y. Breast Cancer. 2017 Sep;24(5):702-707. doi: 10.1007/s12282-017-0761-4. Epub 2017 Feb 20. Breast Cancer. 2017. PMID: 28217830

4

Analysis of circulating tumour cell and the epithelial mesenchymal transition (EMT) status during eribulin-based treatment in 22 patients with metastatic breast cancer: a pilot study.

Horimoto Y, Tokuda E, Murakami F, Uomori T, Himuro T, Nakai K, Orihata G, Iijima K, Togo S, Shimizu H, Saito M. Horimoto Y, et al. J Transl Med. 2018 Oct 20;16(1):287. doi: 10.1186/s12967-018-1663-8. J Transl Med. 2018. PMID: 30342534 Free PMC article. Clinical Trial.

5

Breast Cancer in Lean Postmenopausal Women Might Have Specific Pathological Features.

Uomori T, Horimoto Y, Arakawa A, Iijima K, Saito M. Uomori T, et al. Among authors: horimoto y. In Vivo. 2019 Mar-Apr;33(2):483-487. doi: 10.21873/invivo.11499. In Vivo. 2019. PMID: 30804130 Free PMC article.

6

Impact of circulating tumour cells on survival of eribulin-treated patients with metastatic breast cancer.

Ito M, Horimoto Y, Tokuda E, Murakami F, Uomori T, Himuro T, Nakai K, Orihata G, Iijima K, Saito M. Ito M, et al. Among authors: horimoto y. Med Oncol. 2019 Sep 13;36(10):89. doi: 10.1007/s12032-019-1314-9. Med Oncol. 2019. PMID: 31520329

7

Neutrophil-to-lymphocyte ratio and histological type might predict clinical responses to eriburin-based treatment in patients with metastatic breast cancer.

Myojin M, Horimoto Y, Ito M, Kitano S, Ishizuka Y, Sasaki R, Uomori T, Himuro T, Murakami F, Nakai K, Iijima K, Saito M. Myojin M, et al. Among authors: horimoto y. Breast Cancer. 2020 Jul;27(4):732-738. doi: 10.1007/s12282-020-01069-0. Epub 2020 Feb 27. Breast Cancer. 2020. PMID: 32108306

8

A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience.

Watanabe J, Saito M, Horimoto Y, Nakamoto S. Watanabe J, et al. Among authors: horimoto y. Breast Cancer Res Treat. 2020 May;181(1):211-220. doi: 10.1007/s10549-020-05626-1. Epub 2020 Apr 5. Breast Cancer Res Treat. 2020. PMID: 32249370 Clinical Trial.

9

Primary breast non-Hodgkin's lymphoma in a 14-year-old girl: a case report.

Ishizuka Y, Horimoto Y, Fujimura J, Ogata K, Murakami F, Onagi H, Arakawa A, Saito M. Ishizuka Y, et al. Among authors: horimoto y. Surg Case Rep. 2020 Apr 29;6(1):87. doi: 10.1186/s40792-020-00850-9. Surg Case Rep. 2020. PMID: 32350630 Free PMC article.

10

Ipsilateral breast tumor control following hypofractionated and conventional fractionated whole-breast irradiation for early breast cancer: a long-term follow-up.

Yoshida-Ichikawa Y, Horimoto Y, Shikama N, Yanagisawa N, Koyanagi A, Arakawa A, Saito M, Karasawa K. Yoshida-Ichikawa Y, et al. Among authors: horimoto y. Breast Cancer. 2021 Jan;28(1):92-98. doi: 10.1007/s12282-020-01134-8. Epub 2020 Jul 27. Breast Cancer. 2021. PMID: 32719997

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

165 results

Search Page